Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hemopexin - CSL Behring

Next Previous
X
Search
Drug Profile

Hemopexin - CSL Behring

Alternative Names: CSL-889; Plasma derived hemopexin therapy - CSL Behring

Latest Information Update: 02 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL Behring
  • Class Antianaemics; Beta-globulins
  • Mechanism of Action Hemopexin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Sickle cell anaemia

Most Recent Events

  • 21 Nov 2024 CSL Behring plans a phase II/III trial for Sickle cell anaemia (In adolescent, In adults, In elderly) in February 2025 (IV, Infusion) (NCT06699849, EUCT2024-513440-29-00, CSL889_2001)
  • 13 Jun 2024 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Sickle cell anaemia presented at 29th Congress of the European Haematology Association (EHA-2024)
  • 06 Sep 2023 Phase I development is ongoing in USA (NCT04285827)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top